Cargando…

MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis

BACKGROUND: MDM2 is a major negative regulator of p53, and a single nucleotide polymorphism (SNP) in the MDM2 promoter region SNP309 has been demonstrated to be associated with an increased MDM2 expression and a significantly earlier age of onset of several tumors, including gastric cancer. Several...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yong, Bian, Jianmin, Cao, Hongyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581579/
https://www.ncbi.nlm.nih.gov/pubmed/23451111
http://dx.doi.org/10.1371/journal.pone.0056918
_version_ 1782260443292631040
author Ma, Yong
Bian, Jianmin
Cao, Hongyong
author_facet Ma, Yong
Bian, Jianmin
Cao, Hongyong
author_sort Ma, Yong
collection PubMed
description BACKGROUND: MDM2 is a major negative regulator of p53, and a single nucleotide polymorphism (SNP) in the MDM2 promoter region SNP309 has been demonstrated to be associated with an increased MDM2 expression and a significantly earlier age of onset of several tumors, including gastric cancer. Several studies were published to evaluate the association between SNP309 and gastric cancer risk. However, the results remain conflicting rather than conclusive. OBJECTIVE: The aim of this study was to assess the association between the MDM2 SNP309 polymorphism and gastric risk. METHODS: We performed a meta-analysis to investigate this relationship. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. RESULTS: Five published case-control studies, including 1,621 gastric cancer cases and 2,639 controls were identified. We found that the MDM2 SNP309 polymorphism was associated with a significantly increased risk of gastric cancer risk when all studies were pooled into the meta-analysis (GG versus TT, OR = 1.54; 95%CI = 1.04–2.29, and GG versus GT/TT, OR = 1.49, 95%CI = 1.30–1.72). Furthermore, Egger's test did not show any evidence of publication bias (P = 0.799 for GG versus TT). CONCLUSION: Our results suggest that the MDM2 SNP309 polymorphism may be a low-penetrant risk factor for the development of gastric cancer.
format Online
Article
Text
id pubmed-3581579
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35815792013-02-28 MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis Ma, Yong Bian, Jianmin Cao, Hongyong PLoS One Research Article BACKGROUND: MDM2 is a major negative regulator of p53, and a single nucleotide polymorphism (SNP) in the MDM2 promoter region SNP309 has been demonstrated to be associated with an increased MDM2 expression and a significantly earlier age of onset of several tumors, including gastric cancer. Several studies were published to evaluate the association between SNP309 and gastric cancer risk. However, the results remain conflicting rather than conclusive. OBJECTIVE: The aim of this study was to assess the association between the MDM2 SNP309 polymorphism and gastric risk. METHODS: We performed a meta-analysis to investigate this relationship. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. RESULTS: Five published case-control studies, including 1,621 gastric cancer cases and 2,639 controls were identified. We found that the MDM2 SNP309 polymorphism was associated with a significantly increased risk of gastric cancer risk when all studies were pooled into the meta-analysis (GG versus TT, OR = 1.54; 95%CI = 1.04–2.29, and GG versus GT/TT, OR = 1.49, 95%CI = 1.30–1.72). Furthermore, Egger's test did not show any evidence of publication bias (P = 0.799 for GG versus TT). CONCLUSION: Our results suggest that the MDM2 SNP309 polymorphism may be a low-penetrant risk factor for the development of gastric cancer. Public Library of Science 2013-02-25 /pmc/articles/PMC3581579/ /pubmed/23451111 http://dx.doi.org/10.1371/journal.pone.0056918 Text en © 2013 Ma et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ma, Yong
Bian, Jianmin
Cao, Hongyong
MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis
title MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis
title_full MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis
title_fullStr MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis
title_full_unstemmed MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis
title_short MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis
title_sort mdm2 snp309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581579/
https://www.ncbi.nlm.nih.gov/pubmed/23451111
http://dx.doi.org/10.1371/journal.pone.0056918
work_keys_str_mv AT mayong mdm2snp309rs2279744polymorphismandgastriccancerriskametaanalysis
AT bianjianmin mdm2snp309rs2279744polymorphismandgastriccancerriskametaanalysis
AT caohongyong mdm2snp309rs2279744polymorphismandgastriccancerriskametaanalysis